Minocycline Effectively Prevents Delirium in Critical Patients: CHEST

Written By :  Jacinthlyn Sylvia
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2023-12-20 20:45 GMT   |   Update On 2023-12-21 06:36 GMT

In a recent study, Filipe Dal-Pizzol and colleagues explored the potential of minocycline in preventing delirium among critically ill patients. Delirium, a severe form of acute encephalopathy, poses significant risks to patients in Intensive Care Units (ICUs). The findings were published in CHEST Journal.This randomized, placebo-controlled, double-blind trial conducted across four ICUs and...

Login or Register to read the full article

In a recent study, Filipe Dal-Pizzol and colleagues explored the potential of minocycline in preventing delirium among critically ill patients. Delirium, a severe form of acute encephalopathy, poses significant risks to patients in Intensive Care Units (ICUs). The findings were published in CHEST Journal.

This randomized, placebo-controlled, double-blind trial conducted across four ICUs and aimed to determine if minocycline could be a potential drug in managing this occurrence of delirium. This research included 159 patients and revealed a significant decrease in delirium incidence among those treated with minocycline. Compared to the placebo group, the minocycline recipients showed a lower occurrence of delirium (20% vs. 35%), marking a small but statistically significant improvement.

Beyond delirium incidence, the study explored various secondary outcomes such as delirium/coma free days, length of mechanical ventilation, and mortality rates. Intriguingly, minocycline treatment unexpectedly correlated with a significant decrease in hospital mortality (23% vs. 39%). This unanticipated finding adds a layer of complexity to the potential benefits of minocycline in critical care.

Exploratory outcomes involved monitoring inflammatory and brain-related biomarkers. While the study found a significant decrease in plasma levels of C-reactive protein after minocycline treatment, the broader implications of these changes are yet to be fully understood.

This study opens a promising avenue for future research into the use of minocycline as a neuroprotective agent in critical care settings. The potential to mitigate delirium, coupled with unexpected reductions in mortality, underscores the urgency of more extensive studies to validate these findings and explore the broader applications of minocycline in critical care protocols. Larger and well-structured studies are crucial to confirm the potential benefits of minocycline as a preventive measure against delirium in critically ill patients.

Reference:

Dal-Pizzol, F., Coelho, A., Simon, C. S., Michels, M., Corneo, E., Jeremias, A., Damásio, D., & Ritter, C. (2023). Prophylactic minocycline for delirium in critically ill patients: a randomized controlled trial. In CHEST. Elsevier BV. https://doi.org/10.1016/j.chest.2023.11.041

Tags:    
Article Source : CHEST Journal

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News